Related Insights

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Webinar

Adaptive strategies for more efficient, data-rich and patient-friendly trials

May 28, 2023

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Video

Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Article

Guide for Real-World Evidence

May 21, 2021

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Article

How RWE can help Biotechs optimize the value of their asset

Apr 5, 2021